Neuromodulation

FDA clears Modius Spero headset, a noninvasive at-home neuromodulation therapy that eases PTSD symptoms, with veterans first to access via VA.

MRI-guided SAINT TMS aims to remit treatment-resistant depression in days.

FDA clears MIND1 trial testing NRX-101 plus robotic TMS to curb suicidality in treatment-resistant depression, with military-focused sites.

A multicenter study tests SAINT TMS for postpartum depression.

Explore how TMS offers a World Anti-Doping Agency-safe, nondrug option for athletes.

Innovative combinations of transcranial magnetic stimulation and ketamine therapy offer new hope for treatment-resistant depression, pain, and substance use disorders.

FDA approves ProlivRx, a groundbreaking at-home therapy for major depressive disorder, offering new hope for patients unresponsive to traditional treatments.

Explore how transcranial magnetic stimulation enhances athletic performance and mental health, offering innovative solutions for athletes facing psychological challenges.

Explore the transformative role of TMS in treating depression, its innovative protocols, and future advancements in psychiatric care.

At-home transcranial magnetic stimulation offers a safe, effective way to treat depression, enhancing access and reducing reliance on medications.

FDA expands Deep TMS therapy for adolescents with major depressive disorder, offering a noninvasive treatment option for underserved youth.

Discover how combining transcranial magnetic stimulation and ketamine therapy revolutionizes treatment for complex conditions like depression and pain.

Late-life depression poses unique challenges, impacting cognitive function and requiring tailored treatment strategies for older adults.

Apathy significantly affects cognitive impairment patients, yet remains underrecognized. Discover effective assessment and treatment strategies for improved outcomes.

FDA clears accelerated deep TMS protocol for major depressive disorder, offering faster treatment with similar outcomes and fewer visits.